Subscribe To
Bristol-myers squibb acquisition of mirati makes sense
Bristol Myers Squibb is a large pharmaceutical company with a strong dividend yield and impressive assets. The company's recent acquisition of Mirati ...
October 22, 2023, 8:53 am
Beam: opportunity based on scd data readout in 2024
Beam therapeutics is progressing well with its phase 1/2 BEACON study using BEAM-101 for severe sickle ...
October 22, 2023, 6:39 am
Crispr therapeutics stock: bull vs. bear
The potential for CRISPR therapeutics' pipeline is tremendous. However, an expected product approval ma...
October 21, 2023, 6:45 pm
Harpoon therapeutics announces updated interim tolerability and response data from phase 1/2 clinical trial of t cell engager hpn328 at esmo congress 2023
Confirmed response rate 35% (11/31), across all tumor types and patient cohorts treated with 1 mg priming dose, including three confirmed, complete re...
October 21, 2023, 3:31 pm
Beam therapeutics stock: bear vs. bull
Pre-revenue biotechs like Beam therapeutics bring plenty of risk. The good news is that it has plenty o...
October 21, 2023, 8:45 am
Vivos therapeutics can help you get a better sleep (really)
Better sleep is better health, period. But for many people, it's not that easy....
October 20, 2023, 12:12 pm
Arcutis biotherapeutics shares sink on $100m stock sale
Arcutis Biotherapeutics Inc shares slid more than 18% in pre-market trading on Friday after the early c...
October 20, 2023, 9:13 am
Why is xortx therapeutics (xrtx) stock up 110% today?
Xortx therapeutics (NASDAQ: XRTX ) stock is climbing higher on Friday despite a lack of news from the ...
October 20, 2023, 8:42 am
Arcutis announces pricing of $100 million public offering
WESTLAKE VILLAGE, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQ...
October 20, 2023, 3:45 am
Tourmaline bio announces closing of merger with talaris therapeutics and concurrent private placement of $75 million
Tourmaline will be focused on advancing TOUR006, its differentiated anti-IL-6 antibody, to treat thyroid eye disease (TED), atherosclerotic cardiovasc...
October 19, 2023, 9:37 pm
Allyx therapeutics to present phase 1 data for lead compound alx-001 at the 16th clinical trials on alzheimer’s disease meeting
Allyx’s lead compound, ALX-001, is a small molecule with unique mechanism of action at mGluR5, to protect and preserve synapses in neurodegenerative...
October 19, 2023, 8:05 pm
Why ptc therapeutics soared 15% higher today
The biotech inked a lucrative royalty deal extension. Its counterparty is -- fittingly -- Royalty Pharma....
October 19, 2023, 7:02 pm
Ipo update: chromocell therapeutics seeks $8.7 million in micro-ipo
Chromocell therapeutics Corporation has filed for an $8.7 million IPO to develop its treatment for chro...
October 19, 2023, 5:31 pm
Iovance biotherapeutics: good trade setup created by the fda delay gets even better
Iovance Biotherapeutics: Good Trade Setup Created By The FDA Delay Gets Even Better...
October 19, 2023, 2:35 pm
Excision biotherapeutics announces presentation of interim clinical data for ebt-101 in latent hiv at upcoming european society of gene and cell therapy (esgct) 2023 annual congress
SAN FRANCISCO, Oct. 19, 2023 (GLOBE NEWSWIRE) — Excision Biotherapeutics, Inc., a clinical-stage biot...
October 19, 2023, 11:50 am
Zevra therapeutics celebrates and supports global niemann-pick disease awareness day on october 19th and niemann-pick disease awareness month throughout october
CELEBRATION, Fla., Oct. 19, 2023 (GLOBE NEWSWIRE) — Zevra therapeutics, Inc. (NasdaqGS: ZVRA), a rare...
October 19, 2023, 11:30 am
Kymera therapeutics, inc. (kymr) loses -33.08% in 4 weeks, here's why a trend reversal may be around the corner
Kymera therapeutics, Inc. (KYMR) is technically in oversold territory now, so the heavy selling pressur...
October 19, 2023, 11:21 am
Ptc therapeutics stock jumps on royalty deal worth up to $1.5 billion
PTC therapeutics shares PTCT, -0.53% jumped 12% premarket on Thursday after the company announced a dea...
October 19, 2023, 9:18 am
Beam therapeutics to cut 20% of workforce as part of restructuring plan
Beam therapeutics said on Thursday it plans to reduce its headcount by about 100 employees, or 20% of i...
October 19, 2023, 9:06 am
Beam therapeutics to reduce staff by 20% as it seeks to extend cash runway into 2026
Beam therapeutics Inc. BEAM, -6.60% said Thursday it will reduce headcount by 100 employees, or about 2...
October 19, 2023, 8:56 am